Department of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Zhuzhou Orthopaedic Hospital of Traditional Chinese Medicine, Zhuzhou, 412000, China.
BMC Genomics. 2023 Aug 1;24(1):430. doi: 10.1186/s12864-023-09481-4.
The tumor immune microenvironment (TIME) of colon cancer (CC) has been associated with extensive immune cell infiltration (IMI). Increasing evidence demonstrated that plasma cells (PC) have an extremely important role in advance of antitumor immunity. Nonetheless, there is a lack of comprehensive analyses of PC infiltration in clinical prognosis and immunotherapy in CC. This study systematically addressed the gene expression model and clinical information of CC patients. Clinical samples were obtained from the TCGA (The Cancer Genome Atlas) databases. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), GSVA, and the MAlignant Tumors using Expression data (ESTIMATE) algorithm were employed to research the potential mechanism and pathways. Immunophenoscore (IPS) was obtained to evaluate the immunotherapeutic significance of risk score. Half maximal inhibitory concentration (IC50) of chemotherapeutic medicine was predicted by employing the pRRophetic algorithm. A total of 513 CC samples (including 472 tumor samples and 41 normal samples) were collected from the TCGA-GDC database. Significant black modules and 313 candidate genes were considered PC-related genes by accessing WGCNA. Five pivotal genes were established through multiple analyses, which revealed excellent prognostic. The underlying correlation between risk score with tumor mutation burden (TMB) was further explored. In addition, the risk score was obviously correlated with various tumor immune microenvironment (TIME). Also, risk CC samples showed various signaling pathways activity and different pivotal sensitivities to administering chemotherapy. Finally, the biological roles of the CD177 gene were uncovered in CC.
结直肠癌（CC）的肿瘤免疫微环境（TIME）与广泛的免疫细胞浸润（IMI）有关。越来越多的证据表明浆细胞（PC）在抗肿瘤免疫前具有极其重要的作用。尽管如此，在 CC 的临床预后和免疫治疗中，PC 浸润的综合分析仍然缺乏。本研究系统地研究了 CC 患者的基因表达模型和临床信息。临床样本来自 TCGA（癌症基因组图谱）数据库。使用基因本体论（GO）、京都基因与基因组百科全书（KEGG）、GSVA 和恶性肿瘤使用表达数据（ESTIMATE）算法研究潜在的机制和途径。免疫表型评分（IPS）用于评估风险评分的免疫治疗意义。通过 pRRophetic 算法预测化疗药物的半最大抑制浓度（IC50）。从 TCGA-GDC 数据库共收集了 513 例 CC 样本（包括 472 例肿瘤样本和 41 例正常样本）。通过 WGCNA 访问，认为显著的黑色模块和 313 个候选基因是与 PC 相关的基因。通过多种分析建立了 5 个关键基因，这些基因具有良好的预后。进一步探讨了风险评分与肿瘤突变负担（TMB）之间的潜在相关性。此外，风险评分与各种肿瘤免疫微环境（TIME）明显相关。同样，风险 CC 样本显示出不同的信号通路活性和对化疗药物的不同关键敏感性。最后，揭示了 CD177 基因在 CC 中的生物学作用。
